AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
- REGENERATE-PD, which is now enrolling, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-deriv…
- REGENERATE-PD, which is now enrolling, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-deriv…
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels in th…
Osisko Gold Royalties Ltd (“Osisko” or the “Corporation”) (TSX and NYSE: OR) - https://www.commodity-tv.com/... - is pl…
REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packagi…
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today anno…
As the gene therapy sector continues to mature, regulators’ expectations for more robust product understanding are growi…
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidia…
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances i…
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exc…
- Restructuring Provides Parallel Rights to Manufacture and Sell doggybone DNA (dbDNA™) into the AAV market as Independe…